{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+intravenous+infusion",
    "query": {
      "intervention": "placebo intravenous infusion"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1850,
    "total_pages": 185,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+intravenous+infusion&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T12:37:52.140Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04918719",
      "title": "Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Dextrose in Water",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-11-02",
      "completion_date": "2024-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04918719"
    },
    {
      "nct_id": "NCT01250171",
      "title": "The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "Secukinumab 10 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Canakinumab 10 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 72,
      "start_date": "2010-11",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-01-07",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250171"
    },
    {
      "nct_id": "NCT01130064",
      "title": "Efficacy of QAX576 in Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "QAX576",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 259,
      "start_date": "2010-05",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Huntington Beach, California • Owensboro, Kentucky + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Owensboro",
          "state": "Kentucky"
        },
        {
          "city": "Wheaton",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01130064"
    },
    {
      "nct_id": "NCT04060199",
      "title": "Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Viltolarsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NS Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "7 Years",
        "sex": "MALE",
        "summary": "4 Years to 7 Years · Male only"
      },
      "enrollment_count": 77,
      "start_date": "2020-04-14",
      "completion_date": "2023-10-19",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060199"
    },
    {
      "nct_id": "NCT03008616",
      "title": "Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Severe Preeclampsia"
      ],
      "interventions": [
        {
          "name": "AMAG-423 (digoxin immune fab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2017-04-12",
      "completion_date": "2020-08-13",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 16,
      "location_summary": "Mobile, Alabama • Kansas City, Kansas • Louisville, Kentucky + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03008616"
    },
    {
      "nct_id": "NCT05734716",
      "title": "Colorado-Oregon Altitude Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Mountain Sickness"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Iron sucrose (Venofer)",
          "type": "DRUG"
        },
        {
          "name": "Sterile Sodium Chloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Oregon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 121,
      "start_date": "2021-02-17",
      "completion_date": "2023-01-01",
      "has_results": false,
      "last_update_posted_date": "2023-03-10",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 2,
      "location_summary": "Leadville, Colorado • Eugene, Oregon",
      "locations": [
        {
          "city": "Leadville",
          "state": "Colorado"
        },
        {
          "city": "Eugene",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05734716"
    },
    {
      "nct_id": "NCT04344184",
      "title": "SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Lung Injury, Acute",
        "Kidney Injury"
      ],
      "interventions": [
        {
          "name": "L-ascorbic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2020-12-18",
      "completion_date": "2022-06-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-04",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04344184"
    },
    {
      "nct_id": "NCT03635047",
      "title": "A Phase I Study for Safety and Tolerability of AL002.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "AL002",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Solution",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Alector Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 69,
      "start_date": "2018-11-12",
      "completion_date": "2020-11-25",
      "has_results": false,
      "last_update_posted_date": "2020-12-09",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 4,
      "location_summary": "Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 1 more",
      "locations": [
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03635047"
    },
    {
      "nct_id": "NCT03272165",
      "title": "Single Ascending Dose Study of MEDI1341 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "MEDI1341",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-10-17",
      "completion_date": "2021-03-31",
      "has_results": false,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03272165"
    },
    {
      "nct_id": "NCT02393599",
      "title": "Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Abuse"
      ],
      "interventions": [
        {
          "name": "Lorcaserin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Cocaine Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-05",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-10-01T12:37:52.140Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393599"
    }
  ]
}